Duodenal resurfacing cuts weight after semaglutide
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Duodenal mucosal resurfacing cut weight regain in a blinded, randomized, sham‑controlled trial of patients discontinuing GLP‑1 therapy.
- Ozempic users experience roughly 70% weight regain within 18 months after stopping the drug, underscoring the challenge of maintaining loss.
- Remains‑1 trial participants who received the gut‑reset procedure regained far less weight than sham controls after stopping semaglutide or tirzepatide.
- Shelby Sullivan of Dartmouth Health Weight Center led the study, highlighting the unmet need for durable, non‑drug weight‑maintenance options.
- Dartmouth Health Weight Center performed the minimally invasive outpatient endoscopic ablation that renews duodenal mucosa.
Why it matters: Patients who stop GLP‑1 drugs, about 70% of whom regain weight within 18 months, showed far less rebound after duodenal resurfacing, cutting long‑term obesity‑related healthcare costs and improving metabolic health.
